Across The Globe: Psychedelic Trials To Treat Late-Stage Cancer, Alzheimer's Begin
Across The Globe: Psychedelic Trials To Treat Late-Stage Cancer, Alzheimer's Begin
University of Barcelona's Mercè Pallàs Lliberia and Christian Griñán Ferré will lead the studies.Core One Labs' Akome Partners To Study Next-Gen Psychedelics
核心一個實驗室的合作夥伴研究下一代迷幻藥
A subsidiary of Core One Labs (OTCQB:CLABF) has signed a contract with Fundació Bosh I Gimpera to begin second-phase studies evaluating the therapeutic potential of its bio-compounds (both alone and combined with psychedelic substances).
的附屬公司 核心一實驗室 (OTCQB: CLABF) 已經與簽訂了一份合同 博什我金佩拉基金會 開始第二階段研究評估其生物化合物的治療潛力（單獨和與迷幻物質結合）。
The studies would progress Akome Partners' pre-clinical development stage of novel psychedelic drug alternatives for the treatment of central nervous system (CNS) disorders including Alzheimer's, Parkinson's, ischemic stroke and depression.
該研究將推動 Akome Partners 在新型迷幻藥物替代品的臨床前開發階段，用於治療中樞神經系統（CNS）疾病，包括阿爾茨海默氏症，帕金森氏症，缺血性中風和抑鬱症。
Previous studies conducted by Spanish and Italian institutions included bioassay trials aiming to confirm CNS activity and the underlying neuropathological mechanisms of the targeted diseases. They showed potentially beneficial effects of the plant-based compounds tested and covered in Akome's USPTO patent applications.
西班牙和意大利機構以前進行的研究包括旨在確認中樞神經系統活性和標靶疾病的潛在神經病理機制的生物測定試驗。他們顯示了在 Akome 的 USPTO 專利申請中測試和涵蓋的植物性化合物的潛在有益效果。
University of Barcelona's Mercè Pallàs Lliberia and Christian Griñán Ferré will lead the studies.
巴塞罗那大学 美西帕拉斯利利比里亚 和 克里斯蒂安·格林·费雷 將領導研究。
The goal is to assess how the defects in molecular and cellular processes that cause or contribute to the targeted diseases could be mitigated or prevented with Akome's bio-compounds — both alone and paired in various combinations with active psychedelics.
目標是評估如何使用 Akome 的生物化合物來減輕或預防導致目標疾病的分子和細胞過程中的缺陷-無論是單獨使用還是與活性迷幻藥進行各種組合配對。
See Also: Colorado Voters Approve Initiative To Legalize And Regulate Psychedelics
另請參閱：科羅拉多州選民批准合法化和規範迷幻藥的倡議
Denver Professor Co-Leads Study On Psilocybin Therapy
丹佛教授共同領導裸蓋菇鹼治療研究
Colorado University-Denver professor Jim Grigsby will take part in a study focused on psilocybin-assisted therapy as an alternative treatment to ease the psychological distress of late-stage cancer patients.
科罗拉多大学丹佛教授 吉姆·格里格斯比 將參加一項專注於裸蓋菇素輔助療法的研究，作為一種替代治療方法，以減輕晚期癌症患者的心理困擾。
With $2.1 million in funding from the National Cancer Institute, the study intends to enroll 100 late-stage cancer patients on both the Anschutz Medical and NYU campuses, beginning in February 2023.
該研究計劃從美國國家癌症研究所撥款 210 萬美元，從 2023 年 2 月開始，在安舒茨醫學院和紐約大學校區註冊 100 名後期癌症患者。
The drug session will consist of a single dose of either 25 milligrams of psilocybin or 100 milligrams of niacin (placebo), monitored by a licensed therapist.
該藥物會議將包括任一單劑量 25 毫克裸蓋菇鹼或 100 毫克菸酸（安慰劑），由持牌治療師監測。
The study's endpoints are the effects of psilocybin in the relief of feelings associated such as hopelessness, existential distress, anxiety and depression, all associated with a cancer diagnosis.
該研究的終點是裸蓋菇鹼對緩解相關感覺的影響，例如絕望，存在性困擾，焦慮和抑鬱症，所有這些都與癌症診斷有關。
As for how the psychotherapy component will roll out, Grigsby explained that "therapists sitting next to the person will be minimally directive," allowing people to "turn their attention inward and process whatever comes up."
至於心理治療成分將如何推出，Grigsby 解釋說：「坐在該人旁邊的治療師將受到最低限度的指示」，使人們可以「將注意力轉向內部並處理任何出現的事情。」
After that will come "another six or seven hours of follow-up, non-drug integration of the experience."
之後會來到「另外六七個小時的跟進，非藥物整合的經驗。」
"When this was done at UCLA, Johns Hopkins, and NYU, they found some really interesting results. About 70% to 75% of people will have a very profound experience that is often described as either a direct, mystical type of experience or a psychedelic peak experience. And, often, it is that experience which seems to have a therapeutic effect. That's one of the things we're going to study in this project," the study's PI added.
「當這是在加州大學洛杉磯分校，約翰·霍普金斯大學和紐約大學完成的時候，他們發現了一些非常有趣的結果。大約 70％ 至 75％ 的人會有非常深刻的經驗，通常被描述為直接，神秘的體驗類型或迷幻的高峰體驗。和, 經常, 它似乎具有治療作用的經驗.這是我們在這個項目中要研究的事情之一，」該研究的 PI 補充說。
Grigsby is not new to the world of psychedelic studies. In 2011, he co-led a Phase 2 clinical trial on MDMA for treatment-resistant PTSD, and in 2021 he co-edited a book on medical uses of hallucinogens.
格里格斯比對迷幻研究的世界並不陌生。2011 年，他共同領導了一項針對抗治療 PTSD 的 MDMA 臨床試驗，並於 2021 年共同編輯了一本關於致幻藥物醫療用途的書。
Photo: Benzinga edit with photo by Bacsica, aiyoshi597, Gisele Yashar and Gorodenkoff on Shutterstock.
照片：賓辛加編輯與照片由巴西嘉，aiyoshi597，吉賽爾·亞沙爾和戈羅登科夫在快門特斯托克。
譯文內容由第三人軟體翻譯。
